Serotonin Transporter-Independent Actions of the Antidepressant Vortioxetine As Revealed Using the SERT Met172 Mouse

Alex G. Nackenoff, Linda D. Simmler, Nicole L. Baganz, Alan Pehrson, Connie Sánchez, Randy D. Blakely

Research output: Contribution to journalArticleResearchpeer-review

6 Citations (Scopus)

Abstract

Selective serotonin (5-HT, SERT) reuptake inhibitors (SSRIs) are the most commonly prescribed treatments for depression. However, they have delayed efficacy and can induce side-effects that can encourage discontinuation. Recently, agents have been developed, including vortioxetine (Trintellix), that augment SERT blockade with interactions at other targets. At therapeutic doses, vortioxetine interacts with SERT as well as 5-HT1A, 5-HT1B, 5-HT3, and 5-HT7 receptors. We assessed the SERT-dependency of vortioxetine action using the SERT Met172 mouse model, which disrupts high-affinity interactions of many antidepressants with the transporter. We demonstrate that the SERT Met172 substitution induces an ∼19-fold loss in vortioxetine potency for SERT inhibition in midbrain synaptosomes. Moreover, in these mice, we observed reduced SERT occupancy, a diminished ability to prolong 5-HT clearance, and a reduced capacity to elevate extracellular 5-HT. Despite reduced interactions with SERT, vortioxetine maintained its ability to enhance mobility in tail suspension and forced swim tests, reduce consumption latency in the novelty induced hypophagia test, and promoted proliferation and survival of subgranular zone hippocampal stem cells. Our findings suggest that the antidepressant actions of vortioxetine may be SERT-independent, and encourage consideration of agents that mimic one or more actions of the drug in the development of improved depression treatments.

Original languageEnglish
Pages (from-to)1092-1100
Number of pages9
JournalACS Chemical Neuroscience
Volume8
Issue number5
DOIs
StatePublished - 17 May 2017

Fingerprint

Serotonin Plasma Membrane Transport Proteins
Antidepressive Agents
Serotonin
Hindlimb Suspension
Synaptosomes
Mesencephalon
Stem cells
vortioxetine
Suspensions
Substitution reactions
Stem Cells
Therapeutics
Pharmaceutical Preparations

Keywords

  • SERT Met172
  • Serotonin
  • antidepressant
  • mouse
  • vortioxetine

Cite this

Nackenoff, Alex G. ; Simmler, Linda D. ; Baganz, Nicole L. ; Pehrson, Alan ; Sánchez, Connie ; Blakely, Randy D. / Serotonin Transporter-Independent Actions of the Antidepressant Vortioxetine As Revealed Using the SERT Met172 Mouse. In: ACS Chemical Neuroscience. 2017 ; Vol. 8, No. 5. pp. 1092-1100.
@article{5679133e40c94e09b3a605937b986c00,
title = "Serotonin Transporter-Independent Actions of the Antidepressant Vortioxetine As Revealed Using the SERT Met172 Mouse",
abstract = "Selective serotonin (5-HT, SERT) reuptake inhibitors (SSRIs) are the most commonly prescribed treatments for depression. However, they have delayed efficacy and can induce side-effects that can encourage discontinuation. Recently, agents have been developed, including vortioxetine (Trintellix), that augment SERT blockade with interactions at other targets. At therapeutic doses, vortioxetine interacts with SERT as well as 5-HT1A, 5-HT1B, 5-HT3, and 5-HT7 receptors. We assessed the SERT-dependency of vortioxetine action using the SERT Met172 mouse model, which disrupts high-affinity interactions of many antidepressants with the transporter. We demonstrate that the SERT Met172 substitution induces an ∼19-fold loss in vortioxetine potency for SERT inhibition in midbrain synaptosomes. Moreover, in these mice, we observed reduced SERT occupancy, a diminished ability to prolong 5-HT clearance, and a reduced capacity to elevate extracellular 5-HT. Despite reduced interactions with SERT, vortioxetine maintained its ability to enhance mobility in tail suspension and forced swim tests, reduce consumption latency in the novelty induced hypophagia test, and promoted proliferation and survival of subgranular zone hippocampal stem cells. Our findings suggest that the antidepressant actions of vortioxetine may be SERT-independent, and encourage consideration of agents that mimic one or more actions of the drug in the development of improved depression treatments.",
keywords = "SERT Met172, Serotonin, antidepressant, mouse, vortioxetine",
author = "Nackenoff, {Alex G.} and Simmler, {Linda D.} and Baganz, {Nicole L.} and Alan Pehrson and Connie S{\'a}nchez and Blakely, {Randy D.}",
year = "2017",
month = "5",
day = "17",
doi = "10.1021/acschemneuro.7b00038",
language = "English",
volume = "8",
pages = "1092--1100",
journal = "ACS Chemical Neuroscience",
issn = "1948-7193",
publisher = "American Chemical Society",
number = "5",

}

Serotonin Transporter-Independent Actions of the Antidepressant Vortioxetine As Revealed Using the SERT Met172 Mouse. / Nackenoff, Alex G.; Simmler, Linda D.; Baganz, Nicole L.; Pehrson, Alan; Sánchez, Connie; Blakely, Randy D.

In: ACS Chemical Neuroscience, Vol. 8, No. 5, 17.05.2017, p. 1092-1100.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Serotonin Transporter-Independent Actions of the Antidepressant Vortioxetine As Revealed Using the SERT Met172 Mouse

AU - Nackenoff, Alex G.

AU - Simmler, Linda D.

AU - Baganz, Nicole L.

AU - Pehrson, Alan

AU - Sánchez, Connie

AU - Blakely, Randy D.

PY - 2017/5/17

Y1 - 2017/5/17

N2 - Selective serotonin (5-HT, SERT) reuptake inhibitors (SSRIs) are the most commonly prescribed treatments for depression. However, they have delayed efficacy and can induce side-effects that can encourage discontinuation. Recently, agents have been developed, including vortioxetine (Trintellix), that augment SERT blockade with interactions at other targets. At therapeutic doses, vortioxetine interacts with SERT as well as 5-HT1A, 5-HT1B, 5-HT3, and 5-HT7 receptors. We assessed the SERT-dependency of vortioxetine action using the SERT Met172 mouse model, which disrupts high-affinity interactions of many antidepressants with the transporter. We demonstrate that the SERT Met172 substitution induces an ∼19-fold loss in vortioxetine potency for SERT inhibition in midbrain synaptosomes. Moreover, in these mice, we observed reduced SERT occupancy, a diminished ability to prolong 5-HT clearance, and a reduced capacity to elevate extracellular 5-HT. Despite reduced interactions with SERT, vortioxetine maintained its ability to enhance mobility in tail suspension and forced swim tests, reduce consumption latency in the novelty induced hypophagia test, and promoted proliferation and survival of subgranular zone hippocampal stem cells. Our findings suggest that the antidepressant actions of vortioxetine may be SERT-independent, and encourage consideration of agents that mimic one or more actions of the drug in the development of improved depression treatments.

AB - Selective serotonin (5-HT, SERT) reuptake inhibitors (SSRIs) are the most commonly prescribed treatments for depression. However, they have delayed efficacy and can induce side-effects that can encourage discontinuation. Recently, agents have been developed, including vortioxetine (Trintellix), that augment SERT blockade with interactions at other targets. At therapeutic doses, vortioxetine interacts with SERT as well as 5-HT1A, 5-HT1B, 5-HT3, and 5-HT7 receptors. We assessed the SERT-dependency of vortioxetine action using the SERT Met172 mouse model, which disrupts high-affinity interactions of many antidepressants with the transporter. We demonstrate that the SERT Met172 substitution induces an ∼19-fold loss in vortioxetine potency for SERT inhibition in midbrain synaptosomes. Moreover, in these mice, we observed reduced SERT occupancy, a diminished ability to prolong 5-HT clearance, and a reduced capacity to elevate extracellular 5-HT. Despite reduced interactions with SERT, vortioxetine maintained its ability to enhance mobility in tail suspension and forced swim tests, reduce consumption latency in the novelty induced hypophagia test, and promoted proliferation and survival of subgranular zone hippocampal stem cells. Our findings suggest that the antidepressant actions of vortioxetine may be SERT-independent, and encourage consideration of agents that mimic one or more actions of the drug in the development of improved depression treatments.

KW - SERT Met172

KW - Serotonin

KW - antidepressant

KW - mouse

KW - vortioxetine

UR - http://www.scopus.com/inward/record.url?scp=85019610836&partnerID=8YFLogxK

U2 - 10.1021/acschemneuro.7b00038

DO - 10.1021/acschemneuro.7b00038

M3 - Article

VL - 8

SP - 1092

EP - 1100

JO - ACS Chemical Neuroscience

JF - ACS Chemical Neuroscience

SN - 1948-7193

IS - 5

ER -